J.T. Thigpen - Concepedia

Author

J.T. Thigpen

Also Known As

J T Thigpen, J THIGPEN, J Tate Thigpen, J Thigpen, J. T. Thigpen, J. TATE THIGPEN, J. THIGPEN, J. Tate Thigpen, J. Thigpen, J.T. THIGPEN

266

Publications

12.6K

Citations

H-Index

Concepts

All Affiliations

University of Mississippi Gynecologic Oncology Group University of Mississippi Medical Center Roswell Park Comprehensive Cancer Center Wake Forest University

About

J.T. Thigpen is an author at University of Mississippi specializing in medicine, oncology, and obstetrics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	32	72	5.2K
2	Health Sciences	10	10	908
3	Public Health	7	7	284
4	Allergy	1	1	33
5	Gastroenterology	1	1	23

J.T. Thigpen

Publications

11.7K

Citations

H-Index

Page 1

	Year	Citations
Concurrent Cisplatin-Based Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer Peter G. Rose, Brian N. Bundy, E. Blake Watkins, New England Journal of Medicine	1999	2.6K
Randomized Phase III Trial of Whole-Abdominal Irradiation Versus Doxorubicin and Cisplatin Chemotherapy in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study Marcus E. Randall, Virginia L. Filiaci, Hyman B. Muss, Journal of Clinical Oncology	2005	866
Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240) Krishnansu S. Tewari, Michael W. Sill, Richard T. Penson, The Lancet Advanced Cervical CancerCervical Cancer ManagementCervical CancerCervical HealthMedicine	2017	656
The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume Stage III epithelial ovarian cancer: A gynecologic oncology group study W.J. Hoskins, Brian N. Bundy, J.T. Thigpen, Gynecologic Oncology Cytoreductive SurgeryGynecologic SurgerySurgical OncologyGynecological SurgeryMedicine	1992	553
American Society of Clinical Oncology 2008 Clinical Practice Guideline Update: Use of Chemotherapy and Radiation Therapy Protectants Martee L. Hensley, Karen L. Hagerty, Tarun Kewalramani, Journal of Clinical Oncology	2008	535
Oral Medroxyprogesterone Acetate in the Treatment of Advanced or Recurrent Endometrial Carcinoma: A Dose-Response Study by the Gynecologic Oncology Group J.T. Thigpen, Mark F. Brady, Ronald D. Alvarez, Journal of Clinical Oncology Recurrent Endometrial CarcinomaEndocrine OncologyEndocrine-related CancerMedicineCancer Management	1999	478
Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J.T. Thigpen, John A. Blessing, Harrison Ball, Journal of Clinical Oncology	1994	389
Phase III Trial of Doxorubicin With or Without Cisplatin in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study J.T. Thigpen, Mark F. Brady, Howard D. Homesley, Journal of Clinical Oncology	2004	382
A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas G Omura, Francis J. Major, John A. Blessing, Cancer	1983	357
American Society of Clinical Oncology Clinical Practice Guidelinesfor the Use of Chemotherapy and Radiotherapy Protectants Martee L. Hensley, LynnM. Schuchter, Celeste Lindley, Journal of Clinical Oncology	1999	334

Page 1